13F-HR filed by Medicxi Ventures Management (Jersey) Ltd
Medicxi Ventures Management (Jersey) Ltd filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-01-31, with 6 holding rows worth $238,107,741.
- Accession
- 0000950123-23-000545
- Filer
- CIK 1715579
- Filed
- 2023-01-31
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2022
A holdings report, 6 entries on the cover page, a total value of $238,107,741 stated on the cover page (in dollars after the unit check, H1), rows summing to $238,107,741 with VALUE read as dollars as filed, 13F file number 028-19833. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerFrancesco De Rubertis 028-19836
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| VAXCYTE INC COM | 92243G108 | Stock | 1,457,300 | $69,877,535 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 19,963,157 | $61,885,786 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 3,039,892 | $31,918,866 | dollars as filed | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 2,484,274 | $27,873,554 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 1,600,000 | $24,752,000 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 2,000,000 | $21,800,000 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-23-000545 | this filing | 2023-01-31 | acceptance time not in the bulk data set |